Clinical Trials Logo

Glioblastoma Multiforme clinical trials

View clinical trials related to Glioblastoma Multiforme.

Filter by:

NCT ID: NCT04606316 Active, not recruiting - Glioblastoma Clinical Trials

Surgical Nivolumab And Ipilimumab For Recurrent GBM

Start date: February 1, 2021
Phase: Phase 1
Study type: Interventional

This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma. The names of the study drugs involved in this study are: - Nivolumab - Ipilimumab - Placebo (IV solution with no medicine) - Zr-89 Crefmirlimab berdoxam (optional sub-study)

NCT ID: NCT04588454 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme

PSMA-GBM
Start date: January 17, 2020
Phase: N/A
Study type: Interventional

This is a pilot study to determine uptake of PET tracer 18F-PSMA-1007 in primary glioblastoma.

NCT ID: NCT04471844 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

EF-32
Start date: December 8, 2020
Phase: N/A
Study type: Interventional

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.

NCT ID: NCT04295759 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas

Start date: July 27, 2020
Phase: Phase 1
Study type: Interventional

This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.

NCT ID: NCT04195139 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

NUTMEG
Start date: February 22, 2018
Phase: Phase 2
Study type: Interventional

This study aims to investigate effect of Nivolumab and Temozolomide vs Temozolomide alone on overall survival in newly diagnosed elderly patients with glioblastoma. Who is it for? You may be eligible to join this study if you are aged 65 years or above, with newly diagnosed histologically confirmed GBM (WHO grade IV glioma including gliosarcoma) following surgery. The study aims to evaluate whether the combination of adjuvant nivolumab with temozolomide improves overall survival outcomes for this patient population. The outcome of the study will help determine the most effective treatment for patients with glioblastoma in the future.

NCT ID: NCT03961971 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Start date: February 18, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of stereotactic radiosurgery with MBG453 and spartalizumab in treating patients with recurrent glioblastoma multiforme (GBM). Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor to more precisely target the cancer. Monoclonal antibodies, such as MBG453 and spartalizumab may interfere with the ability of tumor cells to grow and spread. Giving stereotactic radiosurgery together with immunotherapy may be a better treatment for GBM.

NCT ID: NCT03911388 Active, not recruiting - Neoplasms Clinical Trials

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Start date: September 12, 2019
Phase: Phase 1
Study type: Interventional

This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD

NCT ID: NCT03780569 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM

Start date: April 27, 2017
Phase: N/A
Study type: Interventional

The study is a prospective, single arm open label study, designed to test the to evaluate the tolerability and safety outcome of newly diagnosed GBM patients treated with NovoTTF-200A concomitant to Radiotherapy/Temozolomide followed by Temozolomide. The device is a portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

NCT ID: NCT03665545 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

IMA950-106
Start date: October 25, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Monocentric randomized phase I/II trial, including 24 patients diagnosed with relapsing glioblastoma (GBM) irrespective of MGMT and IDH gene status. Following diagnosis of relapsing glioblastoma by either brain CT scan or MRI, patients will be randomized in 2 arms: 1. Arm 1: IMA950 mixed with Poly-ICLC administered subcutaneously 2. Arm 2: Pembrolizumab 200mg q3w IV and IMA950 mixed with Poly-ICLC administered subcutaneously The first phase of treatment will last 6 weeks, then surgery will be performed (done if clinically possible ad indicated). In case of available brain tissue, extensive analysis of the tumor immune response will be performed. Assessment of systemic immune response by PBMC immunomonitoring will be systematically done before and after surgery.

NCT ID: NCT03630289 Active, not recruiting - Glioblastoma Clinical Trials

Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM

Start date: July 27, 2018
Phase: N/A
Study type: Interventional

This study assesses the safety of using tissue autograft of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients. The objective of the study is to demonstrate that this surgical technique is safe in a small human cohort of patients with resected newly diagnosed GBM and may improve progression-free survival (PFS).